What type of study is this?

This is a Systematic Review study.

What question did this study set out to answer?

To evaluate the efficacy of hypomethylating agent therapy in patients with myelodysplastic syndrome with fibrosis (MDS-f).

December 8, 2025Blood

Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis

View Full Paper

Ask AI

Bookmark

Authors

NANajla Al AliMoffitt Cancer Center DSDavid A. SallmanMoffitt Cancer Center EPEric PadronMoffitt Cancer Center

Discussion

Member takes

Overview

Retrospective analysis shows reduced overall survival in myelodysplastic syndrome with fibrosis patients treated with hypomethylating agents, indicating a need for improved strategies.

Key Points

To evaluate the efficacy of hypomethylating agent therapy in patients with myelodysplastic syndrome with fibrosis (MDS-f).
Retrospective observational study at a single center
Patients identified through systematic review of Moffitt Cancer Center MDS Database
Primary endpoint was overall response rate using IWG 2023 criteria
Secondary endpoints included overall survival and incidence of severe treatment-emergent adverse events
Overall response rate in MDS-f was 35.4% compared to 51% in MDS-IB (p=0.006)
Median overall survival was 18.9 months for MDS-f vs. 26.2 months for MDS-IB (p=0.048)
High incidence of treatment-emergent grade IV neutropenia (73.2%) and thrombocytopenia (55.6%) in MDS-f group
Rates of severe complications were similar in patients treated with HMA and venetoclax

Cite This Study

Ali et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d848 https://doi.org/10.1182/blood-2025-3853

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis

View Full Paper

Ask AI

Bookmark

Authors

NANajla Al AliMoffitt Cancer Center DSDavid A. SallmanMoffitt Cancer Center EPEric PadronMoffitt Cancer Center

Discussion

Member takes

Overview

Retrospective analysis shows reduced overall survival in myelodysplastic syndrome with fibrosis patients treated with hypomethylating agents, indicating a need for improved strategies.

Key Points

To evaluate the efficacy of hypomethylating agent therapy in patients with myelodysplastic syndrome with fibrosis (MDS-f).
Retrospective observational study at a single center
Patients identified through systematic review of Moffitt Cancer Center MDS Database
Primary endpoint was overall response rate using IWG 2023 criteria
Secondary endpoints included overall survival and incidence of severe treatment-emergent adverse events
Overall response rate in MDS-f was 35.4% compared to 51% in MDS-IB (p=0.006)
Median overall survival was 18.9 months for MDS-f vs. 26.2 months for MDS-IB (p=0.048)
High incidence of treatment-emergent grade IV neutropenia (73.2%) and thrombocytopenia (55.6%) in MDS-f group
Rates of severe complications were similar in patients treated with HMA and venetoclax

Cite This Study

Ali et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d848 https://doi.org/10.1182/blood-2025-3853

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark